Genetic Engineering and CAR-T Cell Therapy in Hematological Malignancies: From CD19/BCMA Targeting to CRISPR-Enabled Cellular Engineering

Résumé fourni par la source

This research paper explores the rapidly evolving role of genetic engineering and Chimeric Antigen Receptor T-cell (CAR-T) therapy in the treatment of hematological malignancies. It examines major therapeutic targets, particularly CD19 and B-cell maturation antigen (BCMA), and their clinical significance in the management of B-cell leukemias, lymphomas, and multiple myeloma. The paper further highlights the emerging potential of CRISPR-enabled cellular engineering to improve the design, precision, functionality, and therapeutic performance of CAR-T cells. It discusses innovative approaches for enhancing anti-tumor activity, overcoming treatment resistance, developing next-generation allogeneic CAR-T therapies, and improving the safety and persistence of engineered immune cells. The study also addresses important challenges, including cytokine release syndrome, neurotoxicity, antigen escape, tumor heterogeneity, off-target genetic effects, manufacturing complexity, and accessibility. Overall, this work provides an integrated perspective on how CD19/BCMA targeting and CRISPR-based genome engineering are shaping the future of cellular immunotherapy and precision medicine for hematological cancers.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.